Bristol-Myers Squibb shares saw a steep drop of 22.8%, however, analysts still consider them among the
best deep-value stocks to buy. The company shared positive results from a
CAR T therapy trial and is set to bolster its cell therapy portfolio following a $1.5 billion acquisition of
biotech Orbital. Combined with investments in RNA start-ups and AI Consortium partnerships, Bristol-Myers Squibb is positioning itself for
accelerated drug discovery. Its continued contribution to
cancer research development and its impactful work in
neuroscience R&D reflect the company's unwavering commitment to innovation and improving patient lives. Yet, financial performance has been falling, with earnings expected to decline. Its shares have experienced a bigger fall than the market overall. Despite these challenges, the company's restructuring efforts and pricing decisions are garnering investor attention. Furthermore, its commitment to using Veeva Systems' Veeva Vault CRM boosts market confidence. It remains to be seen if these efforts can translate into significant earnings growth.
Bristol-Myers Squibb News Analytics from Mon, 03 Feb 2025 08:00:00 GMT to Sun, 26 Oct 2025 01:35:57 GMT -
Rating -3
- Innovation 7
- Information 8
- Rumor 1
